36.90
-0.39(-1.05%)
Currency In USD
| Previous Close | 37.29 |
| Open | 37.9 |
| Day High | 37.95 |
| Day Low | 36.47 |
| 52-Week High | 63.5 |
| 52-Week Low | 26.2 |
| Volume | 291,931 |
| Average Volume | 895,172 |
| Market Cap | 2.2B |
| PE | -8.91 |
| EPS | -4.14 |
| Moving Average 50 Days | 39.88 |
| Moving Average 200 Days | 40.9 |
| Change | -0.39 |
If you invested $1000 in Apogee Therapeutics, Inc. (APGE) since IPO date, it would be worth $1,738.11 as of August 18, 2025 at a share price of $36.9. Whereas If you bought $1000 worth of Apogee Therapeutics, Inc. (APGE) shares 1 year ago, it would be worth $737.41 as of August 18, 2025 at a share price of $36.9.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis
GlobeNewswire Inc.
Jul 07, 2025 10:00 AM GMT
APEX Part A met all primary and key secondary endpoints and exceeded trial objectives, including 71.0% decrease from baseline in EASI at Week 16 APG777 demonstrated EASI-75 of 66.9% (42.5% placebo-adjusted) at Week 16, the highest topline and placebo
Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025
GlobeNewswire Inc.
Jul 06, 2025 10:00 PM GMT
Webcast to be held Monday, July 7th at 8:00 a.m. ETSAN FRANCISCO and BOSTON, July 06, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with the potential for differ
Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference
GlobeNewswire Inc.
May 29, 2025 11:30 AM GMT
SAN FRANCISCO and BOSTON, May 29, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5,